Adagene (NASDAQ:ADAG) CEO Buys 20,290 Shares of Stock

September 18, 2026 by InsiderTrades.com

Key Points

CEO Peter Luo bought 20,290 Adagene shares at an average price of $3.15, investing approximately $63,914 and increasing his direct stake by 29.73% to 88,535 shares.
Adagene shares opened at $3.37, compared with a 52-week range of $1.30 to $4.85. The company maintains strong reported liquidity, including a 5.02 current ratio, but remains a clinical-stage biopharmaceutical company with ongoing projected losses.
Analyst sentiment is generally favorable, with a consensus “Moderate Buy” rating and an $8.67 target price; however, ratings range from “Sell” to “Buy,” reflecting the risks of early-stage drug development.

Adagene Inc. Sponsored ADR (NASDAQ:ADAG - Get Free Report) CEO Peter Luo acquired 20,290 shares of the stock in a transaction dated Wednesday, September 16th. The shares were purchased at an average price of $3.15 per share, for a total transaction of $63,913.50. Following the completion of the transaction, the chief executive officer owned 88,535 shares of the company's stock, valued at $278,885.25. This trade represents a 29.73% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Peter Luo also recently made the following trade(s):

On Wednesday, August 5th, Peter Luo bought 279 shares of Adagene stock. The stock was purchased at an average cost of $3.65 per share, with a total value of $1,018.35.
On Tuesday, August 4th, Peter Luo purchased 22,966 shares of Adagene stock. The shares were acquired at an average price of $3.65 per share, for a total transaction of $83,825.90.

Adagene Stock Performance

Shares of Adagene stock opened at $3.37 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.02 and a quick ratio of 3.07. The company's fifty day moving average price is $3.68 and its two-hundred day moving average price is $3.73. Adagene Inc. Sponsored ADR has a 52-week low of $1.30 and a 52-week high of $4.85.

More Adagene News

Here are the key news stories impacting Adagene this week:

Positive Sentiment: CEO Peter Luo purchased 20,290 shares at an average price of $3.15, investing approximately $63,914 and increasing his direct ownership by nearly 30%. The transaction may signal management confidence in Adagene’s long-term prospects. SEC insider purchase filing
Positive Sentiment: HC Wainwright reaffirmed a Buy rating and a $7.00 price target, implying substantial upside relative to recent trading levels. The analyst raised projected EPS for 2027 through 2030, with expected losses improving to $0.42 per share in 2027, $0.70 in 2028, $1.07 in 2029 and $0.87 in 2030. Adagene earns Buy rating from HC Wainwright
Positive Sentiment: At the H.C. Wainwright conference, Adagene highlighted its high-dose CTLA-4 therapy, keeping investor attention focused on its immuno-oncology pipeline and potential clinical catalysts. Adagene conference presentation
Neutral Sentiment: The earnings revisions were not uniformly positive: HC Wainwright lowered its FY2026 loss estimate to $0.43 per share from $0.37, while maintaining improving loss forecasts for later years. Adagene’s continuing projected losses and early-stage drug-development risk remain important concerns.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. HC Wainwright reissued a "buy" rating and issued a $7.00 target price on shares of Adagene in a research note on Monday. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Adagene in a report on Friday, July 17th. Guggenheim reiterated a "buy" rating and issued a $10.00 price objective on shares of Adagene in a research note on Tuesday, July 14th. Finally, Chardan Capital began coverage on Adagene in a report on Thursday, September 10th. They issued a "buy" rating and a $9.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $8.67.

View Our Latest Stock Analysis on ADAG

Hedge Funds Weigh In On Adagene

A hedge fund recently raised its position in Adagene stock. Fifth Lane Capital LP raised its position in Adagene Inc. Sponsored ADR (NASDAQ:ADAG - Free Report) by 427.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 145,000 shares of the company's stock after buying an additional 117,500 shares during the period. Fifth Lane Capital LP owned 0.31% of Adagene worth $274,000 as of its most recent SEC filing. Institutional investors and hedge funds own 9.51% of the company's stock.

Adagene Company Profile

(Get Free Report)

Adagene Inc is a clinical-stage biopharmaceutical company focused on discovering and developing antibody-based medicines for cancer and other serious diseases. The company combines computational antibody-design capabilities with laboratory-based discovery and development platforms to create differentiated therapeutic candidates.

Adagene's technology portfolio includes its SAFEbody platform, which is designed to mask antibody binding sites until the medicines reach the tumor microenvironment, potentially improving tumor selectivity and reducing activity in healthy tissue.